SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid shines on receiving final USFDA nod for Rasagiline generic formulation

17 Mar 2016 Evaluate

Orchid Pharma is currently trading at Rs 41.95, up by 4.60 points or 12.32% from its previous closing of Rs. 37.35 on the BSE.

The scrip opened at Rs. 38.30 and has touched a high and low of Rs. 42.70 and Rs. 37.40 respectively. So far 946693 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 75.30 on 06-Aug-2015 and a 52 week low of Rs. 32.60 on 29-Feb-2016.

Last one week high and low of the scrip stood at Rs. 40.35 and Rs. 35.40 respectively. The current market cap of the company is Rs. 375.43 crore.

The promoters holding in the company stood at 38.41% while Institutions and Non-Institutions held 5.39% and 52.41% respectively.

Orchid Pharma has received final approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Rasagiline Tablets 0.5 mg and 1 mg. This product is a FTF (First-to-file) application with a shared 180-day exclusivity for Orchid. Orchid expects to launch this product in Q4 of FY16-17.

Rasagiline Mesylate Tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. With a market size of over $ 300 million and limited generic competition, Orchid hopes to garner a decent market share from this product launch.

Orchid Pharma Share Price

570.50 6.40 (1.13%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×